Peptio

Is retatrutide FDA approved? Status and what is sold

No. FDA has not approved retatrutide and says it cannot be compounded. What regulators found in products sold under its name, and what is unknown.

Peptio Research

On this page8

No. FDA has not approved retatrutide. Its page on unapproved GLP-1 drugs, marked current as of 1 October 2026, says of retatrutide and cagrilintide that "these are not components of FDA-approved drugs", and that FDA has not established their safety and effectiveness for any condition 1. The same page states that retatrutide "cannot be used in compounding under federal law" 1.

Retatrutide is an investigational drug, and its trials are still running. Eli Lilly's phase 3 trial comparing it with tirzepatide is active and no longer recruiting, with an estimated primary completion of November 2026 2. Its trial of cardiovascular and kidney outcomes has an estimated primary completion of February 2029 3.

Lilly also runs a pre-approval expanded access programme, first posted on 5 June 2026 4. It is narrow. Every one of its criteria must be met: an adult with refractory obesity, defined as a BMI of 35 or more despite treatment with the highest available dose of chronic weight management therapy; two or more serious or life-threatening obesity-related complications; no way to join a trial of retatrutide or a comparable investigational medicine; and all standard treatment options, bariatric surgery included, discussed with the patient 4. It lets people who meet those criteria receive Lilly's investigational drug outside a trial. It is not an approval, and "pre-approval" in its title names a stage, not a date 4.

Status by regulator

Regulator Status What its own document says
United States, FDA Not approved Not a component of any FDA-approved drug, safety and effectiveness not established by FDA for any condition, and cannot be used in compounding under federal law. Page current as of 1 October 2026 1
European Union, EMA No entry in EMA's register Neither retatrutide nor LY3437943 has an entry in the register of medicines EMA has assessed, in the copy generated on 2 October 2026. That register covers medicines assessed centrally by EMA. It does not cover authorisations granted by a single member state's national agency 5
United Kingdom, MHRA Not approved Retatrutide is in clinical development and "has not been approved for UK use"; outside authorised clinical trials, products sold in the UK that claim to contain it "are likely to be illegal". Press release of 24 October 2025 6
Australia, TGA Not approved Retatrutide is undergoing clinical trials in humans and "has not been approved by the TGA or any comparable international regulator". Safety advisory of 14 September 2026 7

The phrase "any comparable international regulator" is the TGA's 7. The same advisory says that the supply and advertising of unapproved therapeutic goods in Australia "is prohibited unless a relevant exemption applies" 7. MHRA's statement is the oldest in the table, from October 2025. This page checked FDA, EMA, MHRA and the TGA, and no other regulator.

WADA's Prohibited List could not be retrieved for this page, so it says nothing about retatrutide's status in sport, in either direction.

FDA's documents, EMA's register and the trial registry records cited here were retrieved directly while this page was researched. The TGA and UK government websites could not be reached from the environment used, so the two TGA documents and the two MHRA press releases on this page were read in a browser by a person on 4 October 2026, and their text was recorded for checking 7 8 6 9. Nothing is attributed to them beyond what that text says.

Compounding

FDA's position is the single sentence quoted above: retatrutide "cannot be used in compounding under federal law" 1. Its warning letters give the reasons.

Section 503A of the Federal Food, Drug, and Cosmetic Act provides exemptions for compounded drugs. In letters dated 9 September 2025, FDA set out why retatrutide falls outside them: "Drug products compounded using retatrutide are not eligible for the exemptions provided by section 503A, because retatrutide is not the subject of an applicable USP or NF monograph, is not a component of an FDA-approved human drug, and does not appear on the 503A bulks list." 10 11 12 13 Letters of that date went to companies whose websites, FDA wrote, offered "various compounded drug products, including retatrutide" 11 14 15 12 13.

The separate route in section 503B is closed for the same kind of reason: "Drug products compounded using retatrutide are not eligible for the exemptions provided by section 503B, because retatrutide does not appear on the 503B bulks list, and is not used to compound a drug that appears on the drug shortage list." 10

FDA has also written to a supplier further up the chain. In a letter of 8 December 2025 to a distributor of active pharmaceutical ingredients, it wrote: "Retatrutide is a GLP-1 API that is not identified as an active ingredient in any drug approved by FDA. You distributed this API to pharmacies seeking to compound human drugs under section 503A of the FD&C Act even though retatrutide is not eligible for use in compounding under section 503A." 16

A letter of 20 January 2026 went to a firm registered with FDA as a 503B outsourcing facility, after an FDA inspection of its facility in July 2025. FDA wrote that the firm did not "have any FDA-approved applications on file for the drug products that you repackage, such as Semaglutide, Tirzepatide, and Retatrutide." 17

One FDA release about compounded GLP-1 products does not concern retatrutide specifically. On 3 March 2026 FDA announced "the issuance of 30 warning letters to telehealth companies for making false or misleading claims regarding compounded GLP-1 products", but the release names no individual active ingredient 18. FDA's page on unapproved GLP-1 drugs does name retatrutide in this context. Among those it says it has warned are "Telehealth companies for marketing unapproved drugs such as retatrutide, including instances of direct marketing to consumers" 1.

"Research use only" labels

FDA says it has warned companies that illegally sold unapproved drugs containing semaglutide, tirzepatide, retatrutide, survodutide or mazdutide that were falsely labelled as being for research purposes or not for human consumption 1.

The earliest letters naming retatrutide found for this page date from December 2024. On 17 December 2024 FDA posted "four warning letters to companies for introducing unapproved GLP-1s, including semaglutide, tirzepatide and/or retatrutide products into interstate commerce" 19. Those letters are dated 10 December 2024, and each names retatrutide 20 21 22 23.

Each letter quotes the seller's own labelling and then sets it aside. The labels FDA quoted include:

  • In letters of 10 December 2024: "FOR RESEARCH USE ONLY" and "NOT INTENDED FOR HUMAN USE" 20; "research chemicals only" 21; "RESEARCH USE ONLY" and "INTENDED AS A RESEARCH CHEMICAL ONLY" 22; and "research purposes only" and "not for human consumption or clinical use" 23.
  • In letters of 31 March 2026: "laboratory research purposes only" and "not for human consumption, medical use or veterinary use" 24; and "Research Use Only" and "not intended for human consumption, medical use, or veterinary use" 25.
  • In letters of 24 August 2026: "for research use only" and "not for human or animal consumption" 26; "research use only", "for research and laboratory use only" and "not for human or veterinary use" 27; "for research use only" and "not for human or veterinary use" 28; "for laboratory, research, and analytical use" and "not intended for human or veterinary use" 29; and "research use only" and "not for human consumption" 30.

Then comes the same finding, in nearly the same words each time: despite those statements, "evidence obtained from your website establishes that your products are intended to be drugs for human use" 20 21 23 24 25 26 27 28 29 30. Several of these letters class the products as "unapproved new drugs under section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 355(a)" 24 27 28.

The letters also reproduce sellers' own claims about retatrutide. FDA introduces them as "Examples from your product labeling, including on your website, that provide evidence of the intended use" 24. They are the sellers' words, quoted as evidence against the sellers, and not findings by FDA.

What is in products sold as retatrutide

A label naming retatrutide records what a seller claims. The sources used for this page report laboratory testing of four products in all, and what they found differs 7 31.

In a safety advisory of 14 September 2026, the TGA reported a serious adverse effect linked to a product sold as retatrutide: the consumer had uncontrollable vomiting that resulted in a torn oesophagus, and needed treatment in hospital 7. The TGA obtained a sample of the product in its original unmarked vial. Its laboratory found that the product contained undeclared semaglutide and no retatrutide, and that the amount of semaglutide was approximately 8 times the level found in semaglutide products the TGA has assessed and included in the Australian Register of Therapeutic Goods 7. The TGA's Chief Medical Adviser said: "The biggest risks with unapproved peptide products are not knowing what is in the vial, how much of or even what substance it contains, whether it is sterile, or whether it contains other contaminants or toxins." 7

A published analysis tested three products sold as retatrutide in Australia, each labelled as containing 10 mg, which had been submitted anonymously for testing 31. They contained 5.13 mg (51.3% of the labelled amount), 16.5 mg (165.0%) and 19.0 mg (190.0%) 31. Each contained a peptide matching retatrutide's expected molecular weight, so in these three the failure was the quantity, not the identity 31.

In the United Kingdom, MHRA has described raids on illicit manufacturing, two of which named retatrutide. In a press release of 24 October 2025, it reported dismantling a facility at a warehouse in Northampton, which it called the first illicit production facility for weight loss medicine discovered in the UK 6. Officers seized tens of thousands of empty weight loss pens ready to be filled, raw chemical ingredients, and more than 2,000 unlicensed retatrutide and tirzepatide pens awaiting dispatch to customers, a single figure for the two drugs together 6.

In a press release of 29 May 2026, MHRA reported a raid the previous night on a country estate near Northampton, where two people were arrested on suspicion of offences under the Human Medicines Regulations 2012 9. It recovered around 12,000 doses of unlicensed weight loss medicines, which it called its largest ever seizure of such products; that figure covers everything seized, not retatrutide alone 9. MHRA said the property was believed to have been used to manufacture, assemble and distribute unlicensed weight loss medicines, "including retatrutide and tirzepatide, as well as peptide products" 9. The May release describes itself as the latest of several raids by MHRA's Criminal Enforcement Unit over recent months 9. Neither release reports a laboratory analysis of what the seized products contained 6 9.

In a joint statement of 19 June 2026, the TGA and Australia's Chief Medical Officer named retatrutide among unapproved peptide products that have not been evaluated by the TGA 8. The statement lists what remains unknown about such products: how they are manufactured and whether they meet appropriate quality standards, whether they are sterile, how these peptides act in the human body, and "the nature, frequency and severity of potential side effects" 8. It covers several peptides together, and says that "Some of these products have not undergone sufficient human clinical trials" without saying which 8.

Harms documented outside trials

Two reports of harm in people outside trials are described in the sources used for this page.

The first is the TGA report above: uncontrollable vomiting, a torn oesophagus and treatment in hospital after use of a product sold as retatrutide 7. The TGA's testing of the product found semaglutide and no retatrutide, so whatever caused the harm, the product tested was not retatrutide 7. The advisory does not set out how the TGA assessed the link between the product and the harm.

The second is a published case report of a man in his mid-30s with longstanding type 1 diabetes who presented with severe vomiting, diarrhoea, high blood glucose, ketones in the blood and acute kidney injury shortly after using an online-purchased product marketed as retatrutide for weight loss; his blood ketones peaked at 4.3 mmol/L 32. His partner, who had taken the same preparation, also developed gastrointestinal symptoms, and both had also consumed a potential foodborne source of infection 32. His stool culture grew Shigella. The author writes that "causation cannot be established", and that the timing, the similar symptoms in another exposed person and retatrutide's known gastrointestinal side effects "suggest that exposure may have contributed to symptom severity or amplified the metabolic consequences of infection" 32. The product was not analysed, so the report cannot show what either of them took 32.

FDA's page on unapproved GLP-1 drugs publishes counts of the adverse event reports it had received, as of 31 May 2026, for compounded semaglutide and compounded tirzepatide, and gives no count for retatrutide 1. That is an absence of a published figure, not a figure of zero.

What the trials do and do not tell you

Retatrutide's randomised trials are set out in the review of retatrutide clinical trials, and how they sit beside tirzepatide's in retatrutide vs tirzepatide; they are not restated here. The adverse events recorded in those trials are summarised on the retatrutide page. Every one of those results describes Lilly's investigational product given under trial conditions, and none describes a product bought online, which, as the TGA's testing showed, may not contain retatrutide at all 7.

When it might be approved

Lilly has said when it intends to apply, not that it has applied. In a results release dated 5 August 2026 and filed with the US Securities and Exchange Commission, it states that the clinical data package "is now complete to support global registrations for obesity, obstructive sleep apnea, and knee osteoarthritis pain, with plans to submit a Biologics License Application to the U.S. FDA in the first quarter of 2027" 33. That is the developer's plan, stated by the developer. No document used for this page shows an application filed with FDA or any other regulator, or gives a date for a decision on one, so this page gives none. The other dates on record are trial dates: an estimated primary completion of November 2026 for the trial against tirzepatide, and of February 2029 for the outcomes trial 2 3. Neither is a filing date, and neither says when, or whether, a regulator will approve retatrutide.

Peptides covered

Research areas

Sources

  1. 1. FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss. U.S. Food and Drug Administration. 2026. View source(open access)
  2. 2. A Phase 3, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Retatrutide Compared to Tirzepatide in Adults Who Have Obesity (TRIUMPH-5). ClinicalTrials.gov. 2026. NCT06662383(open access)
  3. 3. A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Event-Driven Study to Investigate the Effect of Retatrutide on the Incidence of Major Adverse Cardiovascular Events and Major Adverse Kidney Events in Participants With Body Mass Index ≥27 kg/m2 and Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (TRIUMPH-Outcomes). ClinicalTrials.gov. 2026. NCT06383390(open access)
  4. 4. Pre-approval Expanded Access of Retatrutide (LY3437943). ClinicalTrials.gov. 2026. NCT07629401(open access)
  5. 5. Medicines output: medicines report (generated 2 October 2026). European Medicines Agency. 2026. View source(open access)
  6. 6. MHRA smashes major illicit weight loss medicine production facility in record seizure. Medicines and Healthcare products Regulatory Agency. 2025. View source(open access)
  7. 7. TGA tests counterfeit retatrutide product following serious adverse event report. Therapeutic Goods Administration. 2026. View source(open access)
  8. 8. Concerns regarding the public health risks associated with unapproved peptide products. Therapeutic Goods Administration. 2026. View source(open access)
  9. 9. Two arrested during the MHRA's largest ever seizure of unlicensed weight loss medicines. Medicines and Healthcare products Regulatory Agency. 2026. View source(open access)
  10. 10. FDA Warning Letter, MARCS-CMS 715883, September 9, 2025. U.S. Food and Drug Administration. 2025. View source(open access)
  11. 11. FDA Warning Letter, MARCS-CMS 716459, September 9, 2025. U.S. Food and Drug Administration. 2025. View source(open access)
  12. 12. FDA Warning Letter, MARCS-CMS 715798, September 9, 2025. U.S. Food and Drug Administration. 2025. View source(open access)
  13. 13. FDA Warning Letter, MARCS-CMS 712126, September 9, 2025. U.S. Food and Drug Administration. 2025. View source(open access)
  14. 14. FDA Warning Letter, MARCS-CMS 713650, September 9, 2025. U.S. Food and Drug Administration. 2025. View source(open access)
  15. 15. FDA Warning Letter, MARCS-CMS 715506, September 9, 2025. U.S. Food and Drug Administration. 2025. View source(open access)
  16. 16. FDA Warning Letter, MARCS-CMS 716152, December 8, 2025. U.S. Food and Drug Administration. 2025. View source(open access)
  17. 17. FDA Warning Letter, MARCS-CMS 718739, January 20, 2026. U.S. Food and Drug Administration. 2026. View source(open access)
  18. 18. FDA Warns 30 Telehealth Companies Against Illegal Marketing of Compounded GLP-1s (press announcement, March 3, 2026). U.S. Food and Drug Administration. 2026. View source(open access)
  19. 19. FDA Roundup: December 17, 2024. U.S. Food and Drug Administration. 2024. View source(open access)
  20. 20. FDA Warning Letter, MARCS-CMS 694608, December 10, 2024. U.S. Food and Drug Administration. 2024. View source(open access)
  21. 21. FDA Warning Letter, MARCS-CMS 695663, December 10, 2024. U.S. Food and Drug Administration. 2024. View source(open access)
  22. 22. FDA Warning Letter, MARCS-CMS 695607, December 10, 2024. U.S. Food and Drug Administration. 2024. View source(open access)
  23. 23. FDA Warning Letter, MARCS-CMS 695156, December 10, 2024. U.S. Food and Drug Administration. 2024. View source(open access)
  24. 24. FDA Warning Letter, MARCS-CMS 721805, March 31, 2026. U.S. Food and Drug Administration. 2026. View source(open access)
  25. 25. FDA Warning Letter, MARCS-CMS 721806, March 31, 2026. U.S. Food and Drug Administration. 2026. View source(open access)
  26. 26. FDA Warning Letter, MARCS-CMS 734884, August 24, 2026. U.S. Food and Drug Administration. 2026. View source(open access)
  27. 27. FDA Warning Letter, MARCS-CMS 735067, August 24, 2026. U.S. Food and Drug Administration. 2026. View source(open access)
  28. 28. FDA Warning Letter, MARCS-CMS 735063, August 24, 2026. U.S. Food and Drug Administration. 2026. View source(open access)
  29. 29. FDA Warning Letter, MARCS-CMS 733652, August 24, 2026. U.S. Food and Drug Administration. 2026. View source(open access)
  30. 30. FDA Warning Letter, MARCS-CMS 735127, August 24, 2026. U.S. Food and Drug Administration. 2026. View source(open access)
  31. 31. Piatkowski T et al. Composition and Labelling Accuracy of Products Sold as Retatrutide in Australia. Drug and Alcohol Review. 2026. PubMed 42559975
  32. 32. Branine N. Online-Sourced Retatrutide Complicating Impending Diabetic Ketoacidosis in a Patient With Type 1 Diabetes and Concurrent Shigella Gastroenteritis. Cureus. 2026. PubMed 42669023(open access)
  33. 33. Lilly reports second-quarter 2026 financial results, raises full-year guidance, and highlights continued growth and pipeline progress (Form 8-K Exhibit 99.1). Eli Lilly and Company, filed with the U.S. Securities and Exchange Commission. 2026. View source(open access)